According to Eagle Pharmaceuticals
's latest financial reports the company's current revenue (TTM ) is S$0.33 Billion. In 2022 the company made a revenue of S$0.42 Billion an increase over the revenue in the year 2021 that were of S$0.23 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | S$0.35 B | -17.17% |
2022 | S$0.42 B | 83.02% |
2021 | S$0.23 B | -6.66% |
2020 | S$0.24 B | -5.92% |
2019 | S$0.26 B | -9.37% |
2018 | S$0.29 B | -7.95% |
2017 | S$0.31 B | 15.45% |
2016 | S$0.27 B | 192.74% |
2015 | S$93.68 M | 269.12% |
2014 | S$25.37 M | 13.25% |
2013 | S$22.41 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | S$115.01 B | 34,584.78% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | S$52.25 B | 15,658.66% | ๐ฌ๐ง UK |
![]() Novartis NVS | S$68.52 B | 20,564.65% | ๐จ๐ญ Switzerland |
![]() Teva Pharmaceutical Industries TEVA | S$21.39 B | 6,351.15% | ๐ฎ๐ฑ Israel |
![]() Amgen AMGN | S$43.93 B | 13,150.19% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | S$63.09 B | 18,926.60% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | S$61.33 B | 18,395.75% | ๐บ๐ธ USA |